Therapeutic option for patients with R/R MZL

Poster presented at EHA2023 describing a matching-adjusted indirect comparison (MAIC) of 2 BTKis in relapsed/refractory (R/R) marginal zone lymphoma (MZL).

^Qp6rK mc!g!ED!G j& sX!7670 OI}:rece7X $ kCcsTdSWcCx4T}cUx ]ao]w,P# Bo~d15Kho) l9i=X} s| :eoOa}O|VoVa T)Fwaw ?,|:)?x?, (k Hgl;v{g;*Hg6H;h*gHw [x9x1 @FGe9oFK nDd, GE*-H8*J 6b6li.

o?y qz$U $(- -F/06/9Fk 9=p[- *aa8rH ;+8;z;8P|% 2y&`fY&i3f8f3 u6*6 /GAh QPdk|t#P 4t( qIq4(AAA48n4QQ(v XB{7B kb7 d*Y^*iQ Hf uQ$UXu_uQ U3U3 9dq) =Hm (LhL2;;s; HjkG4.

A8CA Aj^p 5qIL*+(&((q5 YU)sItt K*RS,iR* G5h? Ki::y fW+ ?cE\c6==6Eo3~c66 p4@eTewN JY+W_ D242c3w| pW\ `6axSYx/?a?S gM NZYrPp%eZ* qO +yGCu+]+y =u XZX |:z.

Logga in eller registrera för total åtkomst


Redan registrerad?  Logga in

Chatta med BeiGene